Intec Pharma (NTEC) IPO Opens Flat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering
August 4, 2015 9:25 AM EDTJERUSALEM, Aug. 4, 2015 /PRNewswire/ -- Intec Pharma Ltd. (the "Company") (NASDAQ: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced the pricing of its initial public offering in the United States of 5,025,000 of its ordinary shares at a price to the public of $6.00 per ordinary share, before underwriting discounts and commissions. All of the ordinary shares are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 753,750 ordinary... More
